What Next for AMARANTUS BIOSCIENCE HOLDINGS INC (OTCMKTS:AMBS) Stock After Increase in Shorted Shares?

April 17, 2018 - By Marguerite Chambers

Amarantus BioScience Holdings, Inc. (OTCMKTS:AMBS) Logo

The stock of AMARANTUS BIOSCIENCE HOLDINGS INC (OTCMKTS:AMBS) registered an increase of 974.58% in short interest. AMBS’s total short interest was 63,400 shares in April as published by FINRA. Its up 974.58% from 5,900 shares, reported previously. The short interest to AMARANTUS BIOSCIENCE HOLDINGS INC’s float is 0.09%.

The stock decreased 6.67% or $0.0032 during the last trading session, reaching $0.0455. About 793,193 shares traded or 91.34% up from the average. Amarantus BioScience Holdings, Inc. (OTCMKTS:AMBS) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company has market cap of $3.11 million. The companyÂ’s diagnostic products in development include the lymphocyte proliferation test, a diagnostic blood test for AlzheimerÂ’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. It currently has negative earnings. The Company’s therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of ParkinsonÂ’s disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.